Status:
ENROLLING_BY_INVITATION
Sanger Human Cell Atlasing Project
Lead Sponsor:
The Wellcome Sanger Institute
Conditions:
Human Development
Genetic Disease
Eligibility:
All Genders
Brief Summary
"Cell Atlasing" refers to a novel strategy to characterise cells in tissues at the molecular level in a quantitative manner. The international Human Cell Atlas consortium brings together a community o...
Detailed Description
Previous methods for quantifying molecular states of cells included microarray and standard RNA-seq analysis on a tissue section (RNA-seq is a technique to look at the activity of all the genes in a c...
Eligibility Criteria
Inclusion
- Samples are from the living and the deceased age 0 to 99+ from healthy and diseased individuals.
- All samples will have fully informed consent for use in research.
Exclusion
- Samples taken without consent for use in future research
- Samples taken from individuals without the capacity to consent to use in research
Key Trial Info
Start Date :
December 16 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 7 2029
Estimated Enrollment :
4000 Patients enrolled
Trial Details
Trial ID
NCT06497673
Start Date
December 16 2019
End Date
November 7 2029
Last Update
July 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wellcome Sanger Institute
Cambridge, United Kingdom